<DOC>
	<DOCNO>NCT01124240</DOCNO>
	<brief_summary>Cilengitide 2000 mg flat i.v . twice weekly administer period 18 month without interruption . Starting one week initiation Cilengitide , RTX ( 60 Gy , 2 Gy per fraction ) concurrent daily temozolomide ( 60 mg/m2 p.o . ) daily procarbazine ( PCB , 50 mg p.o . BSA &lt; 1.7 ; 100 mg p.o . BSA ≥ 1.7 ) give period 6 week ( RTX Monday Friday , TMZ PCB seven day week ) . After break 4 week , adjuvant TMZ ( 50mg/m2 p.o first cycle , 60 mg/m2 p.o . subsequent cycle ) PCB ( 50 mg p.o . BSA &lt; 1.7 ; 100 mg p.o . BSA ≥ 1.7 ) give daily D1 20 . This TMZ/PCB cycle repeat every 28 day total period 6 cycle .</brief_summary>
	<brief_title>Temozolomide Procarbazine With Cilengitide Patients With Glioblastoma Multiforme Without Methylation MGMT Promoter Gene</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<criteria>1 . Newly diagnose supratentorial GBM ( WHO Grade IV , include GBM subtypes , e.g . gliosarcoma ) , histopathologically confirmed central assessment part screen CENTRIC trial . 2 . Males females ≥18 year age . 3 . Proven unmethylated MGMT gene promoter status , centrally assessed part screen CENTRIC trial . 4 . Written inform consent present trial obtain undergoing studyrelated activity . The informed consent also allow access information obtain screen CENTRIC trial , notably result MGMT testing . 5 . Available postoperative GdMRI perform within &lt; 48 hour surgery ( case possible obtain GdMRI within &lt; 48 hour post surgery , GdMRI perform prior randomization ) . 6 . Stable decrease dose steroid &gt; 5 day prior randomization . 7 . ECOG PS 01 . 8 . Interval ≥2 week ≤7 week surgery biopsy first administration study treatment . 9 . Meets one follow RPA classification : Class III ( age &lt; 50 year ECOG PS 0 ) . Class IV ( meet one follow criterion : 1 . Age &lt; 50 year ECOG PS 1 2 . Age ≥50 year , underwent prior partial total tumor resection , Mini Mental State Examination [ MMSE ] ≥27 ) . Class V ( meet one follow criterion : 1 . Age ≥50 year underwent prior partial total tumour resection , MMSE &lt; 27 2 . Age ≥50 year underwent prior tumor biopsy ) . 10 . Laboratory value ( within 2 week prior randomization ) : Absolute neutrophil count ≥1500/mm3 . Platelets ≥ 100,000/mm3 . Creatinine ≤1.5 x upper limit normal ( ULN ) creatinine clearance rate ≥60 mL/min Prothrombin time ( PT ) international normalize ratio ( INR ) partial thromboplastin time ( PTT ) within normal limit . Hemoglobin ≥10 g/dL . Total bilirubin ≤1.5 x ULN . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.5 x ULN ( except attributable anticonvulsant ) . Alkaline phosphatase ≤ 2.5 x ULN . Exclusion criterion Subjects eligible study , fulfill one follow exclusion criterion : 1 . Prior chemotherapy within last 5 year . 2 . Prior RTX head . 3 . Receiving concurrent investigational agent receive investigational agent ( ) within past 30 day prior first dose Cilengitide . 4 . Prior systemic antiangiogenic therapy . 5 . Placement Gliadel® wafer surgery . 6 . Treatment prohibit concomitant medication . 7 . Planned surgery disease ( e.g . dental extraction ) . 8 . History recent peptic ulcer disease ( endoscopically proven gastric ulcer , duodenal ulcer , esophageal ulcer ) within 6 month enrollment . 9 . History malignancy . Subjects curatively treated cervical carcinoma situ basal cell carcinoma skin , subject free malignancy ≥ 5 year eligible study . 10 . History coagulation disorder associate bleed recurrent thrombotic event . 11 . Clinically manifest myocardial insufficiency ( NYHA III , IV ) history myocardial infarction past 6 month . Uncontrolled arterial hypertension . 12 . Concurrent illness , include severe infection , may jeopardize ability subject receive procedure outline protocol reasonable safety . 13 . Subject pregnant ( positive serum beta human chorionic gonadotropin [ βHCG ] test screening ) currently breastfeed , anticipate become pregnant/ impregnating partner study within 6 month study participation , subject agree follow acceptable method birth control , hormonal contraception , intrauterine pessar , condom sterilization , avoid conception study least 6 month receive last dose study treatment . 14 . Current alcohol dependence drug abuse . 15 . Known hypersensitivity study treatment . 16 . Legal incapacity limit legal capacity . 17 . Inability undergo GdMRI . 18 . Presence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule . 19 . Signs symptom suggestive transmissible spongiform encephalopathy , family member suffer ( ed ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Glioblastoma Multiforme</keyword>
</DOC>